Research Article

Optimizing Strategies for Sepsis Management: Lessons from Al-Najaf Teaching Hospital

Abstract

Background: Every year, sepsis is the most common cause of death in hospitalized individuals. Various studies have investigated whether a procalcitonin-guided protocol could optimize the therapeutic approaches in sepsis patients. The evaluation of procalcitonin is a predictive marker for sepsis in individuals admitted to the emergency room or intensive care unit.
Methods: Cross-sectional observational analysis was conducted in the anesthesia department and intensive care unit. It included 100 adult patients enrolled in this study within inclusion criteria for those who have sepsis and septic shock and were admitted to intensive care. A diagnosis of sepsis was taken in a patient with suspected or proven infection. Blood samples from peripheral blood were collected from all patients at admission to measure procalcitonin levels. Follow-up continued until the outcome was determined as discharged well, morbidity occurred, or death was documented.
Results: The higher source of infection was due to a wound (23%). About 55 of the studied patients have a GCS between 13 - 15. The average procalcitonin level when patients were admitted was much higher in those who died or had complications compared to those who were discharged in good health, with a key level of 17.0 µg/L.
Conclusion: Patients with sepsis and other markers can use procalcitonin as a prognostic factor. Lower PCT levels were significantly associated with favourable prognosis.

[1] Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. Jama. 2014;311(13):1308-16.
[2] Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for the management of severe sepsis and septic shock, 2012. Intensive care medicine. 2013;39(2):165-228.
[3] Hines AL, Barrett ML, Jiang HJ, Steiner CA. Conditions With the Largest Number of Adult Hospital Readmissions by Payer, 2011. 2014 Apr. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb–. Statistical Brief #172.
[4] Mayr FB, Yende S, Linde-Zwirble WT, Peck-Palmer OM, Barnato AE, Weissfeld LA, et al. Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis. Jama. 2010;303(24):2495-503.
[5] Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. Jama. 2014;312(1):90-2.
[6] Heffner. SMAC. Septic shock. Treasure Island (FL): StatPearls Publishing; 2020.
[7] Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, et al. Procalcitonin as a prognostic marker for sepsis: a prospective observational study. BMC Res Notes. 2014; 7:458.
[8] Long SS, Prober CG, Fischer M. Principles and practice of pediatric infectious diseases E-Book: Elsevier Health Sciences; 2017.
[9] Sager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Medicine. 2017;15(1):1-11.
[10] Heredia-Rodríguez M, Bustamante-Munguira J, Fierro I, Lorenzo M, Jorge-Monjas P, Gómez-Sánchez E, et al. Procalcitonin cannot be used as a biomarker infection in heart surgery patients with acute kidney injury. J Crit Care. 2016; 33:233-9.
[11] Trippella G, Galli L, De Martino M, Lisi C, Chiappini E. Procalcitonin performance in detecting serious and invasive bacterial infections in children with fever without apparent source: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2017;15(11):1041-57.
[12] Memar MY, Varshochi M, Shokouhi B, Asgharzadeh M, Kafil HS. Procalcitonin: the marker of pediatric bacterial infection. Biomed Pharmacother. 2017; 96:936-43.
[13] Munford RS. Severe sepsis and septic shock. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine. 18th ed. New York: McGraw Hill; 2012. pp. 2223–31.
[14] Bouadma L, Luyt C-E, Tubach F, Chastre J, Wolff M. Procalcitonin in intensive care units: the PRORATA trial–Authors' reply. Lancet. 2010;375(9726):1606-7.
[15] Jekarl DW, Lee S, Kim M, Kim Y, Woo SH, Lee WJ. Procalcitonin as a prognostic marker for sepsis based on SEPSIS‐3. J Clin Lab Anal. 2019;33(9): e22996.
[16] Karlsson S, Heikkinen M, Pettilä V, Alila S, Väisänen S, Pulkki K, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care. 2010;14(6):1-10.
[17] Su L, Feng L, Song Q, Kang H, Zhang X, Liang Z, et al. Diagnostic value of dynamics serum sCD163, sTREM-1, PCT, and CRP in differentiating sepsis, severity assessment, and prognostic prediction. Mediators Inflamm. 2013;2013.
[18] Grozdanovski K, Milenkovic Z, Demiri I, Spasovska K, Cvetanovska M, Kirova-Urosevic V. Early prognosis in patients with community-acquired severe sepsis and septic shock: analysis of 184 consecutive cases. Prilozi. 2012;33(2):105-16.
Files
IssueArticle in Press QRcode
SectionResearch Article(s)
Keywords
Procalcitonin Sepsis ICU
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Al-Awwady AN, Alagha MFH, Yaqoob QA, Sasaa M, Hadrawy HKS. Optimizing Strategies for Sepsis Management: Lessons from Al-Najaf Teaching Hospital. Arch Anesth & Crit Care. 2025;.